These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35394087)

  • 21. SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design.
    Armstrong A; Reddy R; Chadha D; Kircik L
    J Drugs Dermatol; 2022 Apr; 21(4):s5-s10. PubMed ID: 35389593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
    J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
    Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study.
    Amano Y; Mazda J; Amano K; Ohi K; Shioiri T
    BJPsych Open; 2023 Jan; 9(1):e14. PubMed ID: 36636808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial.
    Thianboonsong T; Kanokrungsee S; Paichitrojjana A; Udompataikul M; Kamanamool N; Rojhirunsakool S
    Dermatol Ther; 2020 Nov; 33(6):e14354. PubMed ID: 32990370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of microwave thermolysis energy levels on patient-reported outcomes for axillary hyperhidrosis and osmidrosis.
    Grove GL; Togsverd-Bo K; Schwensen JFB; Andersson NW; Nissen CV; Zachariae C; Haedersdal M
    Lasers Surg Med; 2023 Jan; 55(1):105-115. PubMed ID: 36229952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxybutynin in primary hyperhidrosis: A long-term real-life study.
    Almeida ART; Ferrari F; Restrepo MVS; Rocha VB
    Dermatol Ther; 2020 Nov; 33(6):e14344. PubMed ID: 32981151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pressure-and dose-controlled, needle-free, transcutaneous pneumatic injection of botulinum neurotoxin-A for the treatment of primary axillary and palmoplantar hyperhidrosis.
    Kim HM; Lee MJ; Lee MH; Lee H
    Skin Res Technol; 2020 Jul; 26(4):577-583. PubMed ID: 31922304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Direct Current Administration on Hyperhidrosis Disease Severity Scale in Patients with Axillary Hyperhidrosis.
    Şener S; Karakoç Y
    Biomed Res Int; 2019; 2019():3232015. PubMed ID: 31781610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case series evaluating microwave-based therapy for axillary hyperhidrosis and bromhidrosis.
    Mohamoud AA; Zeraiq L; Vestergaard T
    J Dermatolog Treat; 2022 May; 33(3):1572-1575. PubMed ID: 33622150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
    Nasir A; Bissonnette R; Maari C; DuBois J; Pene Dumitrescu T; Haddad J; Yamaguchi Y; Dalessandro M
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):145-151. PubMed ID: 29055158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Pilot Study of the Safety and Effectiveness of a Novel Device in Subjects With Axillary Hyperhidrosis.
    Kaufman J; Green JB; Cazzaniga A; Canty DJ; Tims E; Waugh J
    Dermatol Surg; 2022 Nov; 48(11):1220-1225. PubMed ID: 36129240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and prolonged efficacy of Botulin Toxin A in primary hyperhidrosis.
    D'Epiro S; Macaluso L; Salvi M; Luci C; Mattozzi C; Marzocca F; Salvo V; Scarnò M; Calvieri S; Richetta AG
    Clin Ter; 2014; 165(6):e395-400. PubMed ID: 25524193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bilateral one-stage single-port sympathicotomy in primary focal hyperhidrosis, a prospective cohort study: treat earlier?
    Kuijpers M; Peeters G; Harms PW; Bouma W; DeJongste MJ; Mariani MA; Klinkenberg TJ
    J Cardiothorac Surg; 2021 Mar; 16(1):50. PubMed ID: 33766091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: A prospective, randomized, controlled, split-area comparative trial.
    Kaminaka C; Mikita N; Inaba Y; Kunimoto K; Okuhira H; Jinnin M; Kao B; Tanino R; Tanioka K; Shimokawa T; Yamamoto Y
    Lasers Surg Med; 2019 Sep; 51(7):592-599. PubMed ID: 30811620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
    Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
    Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review.
    Cruddas L; Baker DM
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):952-963. PubMed ID: 27976476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis].
    Hund M; Sinkgraven R; Rzany B
    J Dtsch Dermatol Ges; 2004 May; 2(5):343-9. PubMed ID: 16281522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durability of botulinum toxin treatment for axillary hyperhidrosis.
    Moffat CE; Hayes WG; Nyamekye IK
    Eur J Vasc Endovasc Surg; 2009 Aug; 38(2):188-91. PubMed ID: 19395290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.